Market Spotlight: Myelofibrosis (MF)

Market Spotlight: Myelofibrosis (MF)

  • June 2021 •
  • 44 pages •
  • Report ID: 5955566 •
  • Format: PDF
This Market Spotlight report covers the Myelofibrosis (MF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
The analyst estimates that in 2019, there were 49,500 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 60,700 prevalent cases by 2028.
Bristol Myers Squibb’s Inrebic and Incyte’s Jakafi are the only marketed drugs for myelofibrosis. These drugs are administered via the oral route.
The majority of industry-sponsored drugs in active clinical development for myelofibrosis are in Phase II, with one drug in the NDA/BLA stage.
Therapies in development for myelofibrosis focus on a wide variety of targets. The majority of the pipeline drugs are administered via the oral route.
High-impact upcoming events for drugs in the myelofibrosis space comprise topline Phase III trial results for pacritinib, Reblozyl, momelotinib, and imetelstat, as well as an estimated PDUFA date for pacritinib.
The overall likelihood of approval of a Phase I hematologic asset is 8.6%, and the average probability a drug advances from Phase III is 59.1%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.6 years in the overall oncology space
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for myelofibrosis have been in the early and mid-phases of development, with 80% of trials in Phase I–II, and only 20% in Phase III–IV.
The US has a substantial lead in the number of myelofibrosis clinical trials globally. Germany leads the major European markets, while Israel has the top spot in Asia.
Novartis has the highest number of completed clinical trials for myelofibrosis, with 15 trials.
Novartis leads industry sponsors with the highest overall number of clinical trials for myelofibrosis, followed by Incyte.